Coeptis Therapeutics Holdings, Inc. - Warrants

Share · US19207A1161 · COEPW (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Coeptis Therapeutics Holdings, Inc. - Warrants

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

24.04.2026 23:56

Current Prices from Coeptis Therapeutics Holdings, Inc. - Warrants

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	COEPW	USD	24.04.2026 23:56	0,010 USD	-
IEX	COEPW	USD	24.04.2026 15:11	0,02 USD	-

Share Float & Liquidity

Free Float 83,44 %

Shares Float 5,19 M

Shares Outstanding 6,22 M

Company Profile for Coeptis Therapeutics Holdings, Inc. - Warrants Share

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.